Please provide your email address to receive an email when new articles are posted on . The researchers added that, “subsequently, [biosimilar adalimumab] effectiveness and safety were proved in two ...

Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics ...

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Sandoz said that ...

Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). Sandoz ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

Novartis NVS announced new long-term follow-up data from the ongoing, pivotal open-label ENESTfreedom and ENESTop trials. The data from the trials showed sustained treatment-free remission (TFR) after ...

(RTTNews) - Sandoz (SDZNY) has unveiled Hyrimoz or adalimumab citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, ...

Sandoz has received a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for a citrate-free high concentration formulation (HCF) of its ...